Press release
European Academy of Allergy and Clinical Immunology (EAACI) Congress 2020 goes digital
Under the increasingly pertinent motto "Bridging innovations into Allergy and Asthma Prevention", we will offer the opportunity to explore the rich scientific programme in a truly innovative way. Sessions will delve into omics, big data, mHealth and the development of artificial intelligence, endotype and theratype approaches that change not only the taxonomy but the way we perceive and manage allergic diseases.
What better way to be updated on the conceptual and technological advances in our field, than by taking part in a brand-new technological approach to our EAACI Annual Congress?
Over a three-day period, participants can tune in and watch a variety of virtual sessions, while having the possibility to discuss important topics with the speakers via the interactive Q&A. Our vast number of abstracts, posters, and webcast symposia and workshops with novel research being undertaken by our experts worldwide can be consulted online at any time during the congress period and subsequently over the summer.
Virtual congresses provide many advantages for speakers and participants: flexibility; a wider reach that can aid the dissemination of your work to a larger international audience; the ability to watch multiple symposia and access all the information without missing out and in your own time; and the possibility to still interact and network with your peers through our tailored web-based solutions.
While we look forward to seeing you again in person at EAACI Congress 2021, we hope you will contribute to making the first ever digital EAACI Annual Congress a success in 2020, through your participation, state-of the-art science and adaptability. The EAACI Family is an impressive network of dedicated specialists, let's work together to stay connected and extend our reach and break-through science via digital means and beyond the existing barriers.
Stay tuned on EAACI.org for updated information on registration, congress logistics and the upcoming scientific programme which will be announced shortly.
EAACI Congress 2020 | EAACI.org
Press Contact
European Academy of Allergy and Clinical Immunology (EAACI)
111 Hagenholzstrasse
8050 Zurich Switzerland
Chiara Hartmann
Chiara.hartmann@eaaci.org
The European Academy of Allergy and Clinical Immunology, EAACI, is an association including over 70 European National Societies, more than 11'500 academicians, research investigators and clinicians working to improve the lives of allergic patients.
www.eaaci.org
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release European Academy of Allergy and Clinical Immunology (EAACI) Congress 2020 goes digital here
News-ID: 2014740 • Views: …
More Releases for EAACI
Allergic Rhinitis Drugs Market Competitive Analysis and Vendor Landscape by 2026 …
Allergic rhinitis or hay fever is an IgE-mediated disorder caused by allergens such as mold or tress, animal, dander, house dust mites, weed pollens, and grass. It can occur in two different forms namely, seasonal and perennial, which in turn causes mild or moderate to severe inflammation inside the nose. Some of the major symptoms of allergic rhinitis include nasal congestion, rhinorrhea, sneezing, nasal itching, and itchy eyes, or it…
Allergy Treatment Market Insights with Statistics and Growth Prediction 2018 to …
An allergy is defined as a reaction of hypersensitivity to several foreign substances by the immune system. The substances that trigger an allergy are called allergens. Examples include pollens, dust mites, molds, pet dander, certain foods, and others. It is said that patients prone to allergies are allergic or atopic.
The market for allergy treatment is expected to grow at an accelerated pace due to the increased focus on new…
Allergy Treatment Market - Innovative Developments by 2025 | GlaxoSmithKline, Sa …
An allergy is defined as a hypersensitive reaction to various foreign substances by the immune system. The substances that trigger an allergy are called allergens. Examples include pollens, dust mite, molds, pet dander, certain foods, and others. Patients prone to allergies are said to be allergic or atopic.
The allergy treatment market is anticipated to grow at a fast pace owing to the rise in focus on new treatment developments…
Allergy Treatment Market Anticipated to Grow High with an Impressive Rate during …
Allergy Treatment Market was valued at $24,653 million in 2017 and is projected to reach $40,360 million by 2025, growing at a CAGR of 6.3% from 2018 to 2025. Based on type, the rhinitis and asthma segments accounted for more than half of the total market share in 2017.
An allergy is defined as a hypersensitive reaction to various foreign substances by the immune system. The substances that trigger an allergy…
Antihistamine Drugs Global Market 2018-2023: Key Players - Johnson & Johnson Con …
Market Scenario
Antihistamines are drugs mainly used for treating allergies. They are also used to treat motion sickness, insomnia and anxiety. They work by acting against a chemical called histamine which leads to many allergic symptoms. Antihistamines may cause side effects such as dizziness, dry mouth, nervousness, irritability, blurry vision and decreased appetite.
The global antihistamine drugs market is expected to grow at a CAGR of 9.8% during the forecast period and…
Antihistamine Drugs Market Is Expected To Grow At CAGR 9.8% With Sanofi, Bayer A …
Market Scenario
Antihistamines are drugs mainly used for treating allergies. They are also used to treat motion sickness, insomnia and anxiety. They work by acting against a chemical called histamine which leads to many allergic symptoms. Antihistamines may cause side effects such as dizziness, dry mouth, nervousness, irritability, blurry vision and decreased appetite.
The global antihistamine drugs market is expected to grow at a CAGR of 9.8% during the forecast period and…
